Brittany T Rupp, Joaquin Reyna, Ally Giunta, Theresa Weaver, Kelly Chason, Jinze Liu, Ajay S Gulati, Kevin M Byrd
{"title":"Interpretable machine learning applied to high-dimensional salivary proteomics in pediatric inflammatory bowel diseases.","authors":"Brittany T Rupp, Joaquin Reyna, Ally Giunta, Theresa Weaver, Kelly Chason, Jinze Liu, Ajay S Gulati, Kevin M Byrd","doi":"10.1093/ibd/izag181","DOIUrl":"10.1093/ibd/izag181","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), ulcerative colitis (UC), and inflammatory bowel disease unclassified (IBD-U), are chronic inflammatory disorders of the gastrointestinal tract. Current methods for classification and longitudinal monitoring are invasive, expensive, and often delayed, limiting timely diagnosis and management. This proof-of-concept study reports the first application of high-dimensional salivary proteomics integrated with interpretable artificial intelligence/machine learning (ML) to define a minimal protein signature for pediatric IBD classification with the ultimate goal of informing therapeutic decision-making.</p><p><strong>Methods: </strong>Unstimulated saliva from pediatric CD, UC, and IBD-U patients was analyzed using Alamar Biosciences' NULISAseq 250 Protein Inflammation Panel. Logistic regression with recursive feature elimination identified a candidate minimal discriminative signature. Performance was further assessed using follow-up samples. SHAP (SHapley Additive exPlanations) quantified patient-specific protein contributions and assessed biological similarity of IBD-U to CD and UC.</p><p><strong>Results: </strong>Differential abundance analysis between UC and CD revealed 53 significantly different proteins. ML identified a 14-protein signature comprising chemokines/cytokines (CCL1, IFNA1-IFNA13, IL12p70, IL34, TNFSF11/RANKL), receptors/ligands (CD40LG, ICOSLG, IL1R2, IL17RA), structural/tissue-remodeling proteins (CD93, GFAP, SPP1), and growth factors/immune modulators (GDF2, GZMA). The proposed model achieved 97.5% balanced accuracy in first-visit pilot samples and 80.2% with matched follow-up samples. SHAP revealed patient-specific drivers and suggested biological alignment of IBD-U cases toward CD- or UC-like profiles.</p><p><strong>Conclusions: </strong>This first-in-field integration of salivary proteomics with interpretable artificial intelligence/ML demonstrates that accurate, noninvasive classification of pediatric IBD is possible using minimal biomarker sets. This approach establishes a scalable framework for future longitudinal monitoring and supports earlier and more precise therapeutic interventions.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149378809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dhamyanthi Thangarajah, Karyn Chappell, Anyavathi Helena Burtt, Gary Frost, John M E Fell
{"title":"Response to Letter \"Visceral adiposity in pediatric Crohn disease: phenotype or disease-activity biomarker?\"","authors":"Dhamyanthi Thangarajah, Karyn Chappell, Anyavathi Helena Burtt, Gary Frost, John M E Fell","doi":"10.1093/ibd/izag232","DOIUrl":"10.1093/ibd/izag232","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shunsuke Horitani, Anna Horitani, Christopher J Tyler, Makoto Naganuma, Peter B Ernst, Davey Smith, Derek R Patel, Brian Behm, Andres Yarur, Jesús Rivera-Nieves
{"title":"Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis.","authors":"Shunsuke Horitani, Anna Horitani, Christopher J Tyler, Makoto Naganuma, Peter B Ernst, Davey Smith, Derek R Patel, Brian Behm, Andres Yarur, Jesús Rivera-Nieves","doi":"10.1093/ibd/izag242","DOIUrl":"https://doi.org/10.1093/ibd/izag242","url":null,"abstract":"<p><strong>Background and aims: </strong>Vedolizumab (VDZ) blocks integrin α4β7-MAdCAM-1 interactions, limiting leukocyte entry into the gut, yet peripheral-blood immune correlates of clinical response in ulcerative colitis (UC) remain unidentified.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells from healthy controls (HCs) and patients with UC, stratified by VDZ exposure and clinical response, were analyzed using mass cytometry (cytometry by time-of-flight). A 38-marker panel enriched for integrins, chemokine receptors, and activation markers was applied. Major immune populations were interrogated using lineage-specific opt-SNE and FlowSOM clustering.</p><p><strong>Results: </strong>The dataset included 26 HCs, 30 VDZ-naive UC (Nancy index ≥ 2), 8 VDZ-treated non-responders (Nancy index ≥ 2), and 8 VDZ-treated responders (Nancy index <2). No significant differences were detected in myeloid, NK-cell, or TCRγδ+ T-cell compartments. Integrin α4β7+ cells were detected across multiple immune lineages and were enriched in the B-cell compartment. Between-group differences were observed in the CD4+ T-cell and B-cell compartments. VDZ responders showed enrichment of an α4β7+ effector memory CD4+ T-cell subset compared with VDZ-naive UC. In parallel, responders exhibited reduced frequencies of class-switched plasmablast and activated B-cell populations relative to VDZ-naive UC. Integrin-pairing analysis demonstrated that these B-cell populations contained both α4β7+ and α4β1+ cells. In contrast, VDZ non-responders showed enrichment of an α4β7+ atypical-like IgA+ memory B-cell subset relative to responders, VDZ-naive UC, and HCs.</p><p><strong>Conclusions: </strong>Clinical response and non-response to VDZ in UC are associated with distinct circulating T- and B-cell immune phenotypes. Peripheral-blood immunophenotyping may identify correlates of response and non-response. Prospective studies are needed to determine whether these signatures are predictive before VDZ initiation or reflect pharmacodynamic changes after treatment.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zoë S Gottlieb, Benita Glamour, Drew Helmus, Marla C Dubinsky
{"title":"Trends in common laboratory markers during pregnancy in women with IBD in clinical remission.","authors":"Zoë S Gottlieb, Benita Glamour, Drew Helmus, Marla C Dubinsky","doi":"10.1093/ibd/izag217","DOIUrl":"https://doi.org/10.1093/ibd/izag217","url":null,"abstract":"<p><strong>Background: </strong>Physiologic pregnancy changes can alter commonly monitored laboratory values and mimic active inflammatory bowel disease (IBD), complicating prenatal disease monitoring. Biomarker trajectories in women with IBD in remission are not well established. We aimed to characterize trimester-specific changes in key biomarkers among women with IBD in remission before and throughout pregnancy.</p><p><strong>Methods: </strong>We performed a retrospective review of pregnant women with IBD in remission enrolled in a prospective preconception/pregnancy registry. Eligible patients had laboratory data from the preconception period and at least 1 trimester (first trimester [T1], second trimester [T2], or third trimester [T3]). Parameters included complete blood counts, albumin, C-reactive protein, erythrocyte sedimentation rate (ESR), iron studies, and fecal calprotectin (FC). Changes from preconception were assessed using Wilcoxon signed rank tests and McNemar's test when applicable.</p><p><strong>Results: </strong>Sixty-eight pregnancies from 61 women were included (68.9% Crohn's disease, 27.9% ulcerative colitis; median age 33 years; 83.8% on biologics). Compared with preconception, ESR and white blood cell count rose across trimesters (ESR PT2T3 < .001; white blood cell PT1-T3 < .001). Hemoglobin, hematocrit, platelets, and albumin declined significantly, particularly in T2/T3 (all P ≤ .008). C-reactive protein rose during all trimesters (PT1 = .003; PT2, T3 < .001), whereas FC remained stable and within normal range throughout pregnancy (all P > .05). Most biomarkers trended toward baseline postpartum.</p><p><strong>Conclusions: </strong>In pregnant women with IBD in remission, most laboratory changes appear physiologic, requiring cautious interpretation. FC was the only stable biomarker throughout pregnancy and remains the most reliable marker of inflammation during this period. These trimester-specific data may improve interpretation of biomarkers in pregnant patients with IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effects of upadacitinib on lipid profiles and their relationship with inflammation in patients with inflammatory bowel disease: a real-world longitudinal cohort study.","authors":"Shengduo He, Wei Zhang, Yuling Tian, Chaoyi Ge, Guigen Teng, Junxia Li, Huahong Wang, Yun Dai, Yu Tian","doi":"10.1093/ibd/izag241","DOIUrl":"https://doi.org/10.1093/ibd/izag241","url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib (UPA), a selective Janus kinase 1 inhibitor, is approved for moderate-to-severe inflammatory bowel disease (IBD). JAK inhibitors affect lipid metabolism, but longitudinal real-world data on lipid changes during UPA therapy, and their relation to inflammatory activity, are scarce.</p><p><strong>Methods: </strong>In this single-center retrospective cohort study, patients with ulcerative colitis or Crohn's disease treated with upadacitinib were followed for up to 2 years. Serial fasting lipid profiles and inflammatory markers (fecal calprotectin, C-reactive protein [CRP], high-sensitivity CRP) were collected at baseline, end of induction (weeks 8-12), 1 year, and 2 years. Lipid trajectories were analyzed with linear mixed-effects models; paired changes were compared with paired t-tests.</p><p><strong>Results: </strong>Among 159 patients (mean age 43.3 ± 14.0 years; 62.3% male), total cholesterol (TC) rose from 4.19 ± 0.87 mmol/L at baseline to 4.92, 5.03, and 5.21 mmol/L at the end of induction, 1 year, and 2 years (mixed-effects estimates +0.70 to +0.90; all P < .001). Low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) rose in parallel, and the LDL-C/HDL-C ratio did not increase. CRP reductions correlated with lipid rises (Spearman rho = -0.45 to -0.47; all P ≤ .02). No cardiovascular death, myocardial infarction, or stroke occurred (0/159); one venous thromboembolism and 3 hypertension cases were recorded.</p><p><strong>Conclusions: </strong>In patients with IBD treated with UPA, TC and LDL-C rose modestly alongside the resolution of inflammation; HDL-C improved and the LDL-C/HDL-C ratio did not increase. Lipid monitoring and individualized cardiovascular risk assessment are warranted during UPA therapy.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cindy C Y Law, Arafa Djalal, Mason Hopkins, Dakota Trick, Thierry Dervieux, Catherine Rowan, Jean-Frederic Colombel
{"title":"Performance of an infliximab precision-guided dosing tool from a capillary blood-based self-collection device in inflammatory bowel disease patients.","authors":"Cindy C Y Law, Arafa Djalal, Mason Hopkins, Dakota Trick, Thierry Dervieux, Catherine Rowan, Jean-Frederic Colombel","doi":"10.1093/ibd/izag214","DOIUrl":"https://doi.org/10.1093/ibd/izag214","url":null,"abstract":"<p><strong>Background and aims: </strong>Infliximab (IFX) trough concentrations are routinely measured to guide dosing and optimize efficacy. Bayesian forecasting tools may enable earlier prediction of trough concentrations, while patient-friendly capillary self-collection devices could improve access to precision-guided dosing (PGD). We evaluated the performance of the PredictrPK IFX platform in forecasting IFX trough concentrations by using serum collected with an upper-arm self-collection device and compared its performance with standard venous blood obtained by phlebotomy.</p><p><strong>Methods: </strong>Patients with inflammatory bowel disease (IBD) receiving IFX maintenance therapy were recruited from a single IBD center. Midcycle samples collected via an upper-arm self-collection device and via traditional venipuncture were compared. The IFX clearance was estimated by use of a nonlinear mixed-effects model with Bayesian priors and the predicted IFX levels were compared with measured trough concentrations obtained prior to infusions. Deming regression was used for statistical analysis.</p><p><strong>Results: </strong>The study included 57 patients (61% males, median age, 34 years). The median IFX dose was 10 mg/kg with a median interdose interval of 6 weeks. A total of 97 capillary and venous blood pairs were tested. Concentrations of IFX from venous and capillary blood samples demonstrated strong correlations (R2 = 0.987, Demings = 1.08). There was also a strong association between predicted IFX concentrations and measured IFX trough concentrations.</p><p><strong>Conclusion: </strong>PredictrPK accurately predicted IFX trough concentrations. Capillary self-collection using an upper-arm device yielded results comparable to those from venous blood measurement, which may facilitate increased implementation and accessibility of PGD in clinical practice.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kexin Guo, Jonathan Golob, Jeffrey Berinstein, Jessica Sheehan, William D Chey, Peter D R Higgins, Vincent Young, Krishna Rao, Prashant Singh, Shrinivas Bishu, Allen Lee
{"title":"Mucosal transcriptomic and fecal microbiome signatures associated with persistent symptoms in quiescent Crohn's disease.","authors":"Kexin Guo, Jonathan Golob, Jeffrey Berinstein, Jessica Sheehan, William D Chey, Peter D R Higgins, Vincent Young, Krishna Rao, Prashant Singh, Shrinivas Bishu, Allen Lee","doi":"10.1093/ibd/izag244","DOIUrl":"https://doi.org/10.1093/ibd/izag244","url":null,"abstract":"<p><strong>Background: </strong>Persistent symptoms in quiescent Crohn's disease (qCD + S) lack clear mechanistic explanations. Building on prior evidence linking qCD + S to sulfidogenic microbial metabolism, this study characterizes the underlying site-specific mucosal transcriptional programs and host-microbe interactions associated with qCD + S.</p><p><strong>Methods: </strong>We integrated paired metagenomic and transcriptomic data from a cross-sectional cohort of patients with qCD. Host-microbe interactions in the ileum and rectosigmoid colon were analyzed using differential expression, penalized regression, and sparse canonical correlation analysis.</p><p><strong>Results: </strong>qCD + S was associated with transcriptional differences in separate analyses of ileal and rectosigmoid samples. The ileum showed reduced expression of genes related to immune surveillance, whereas the rectosigmoid colon exhibited reduced chemokine-related and increased ribosomal gene expression. Multi-omic integration identified associations between previously identified sulfidogenic microbes and mucosal genes related to mitochondrial metabolism, epithelial homeostasis, and neurosensory signaling. Exploratory sparse canonical correlation analysis identified multivariate patterns involving oral-associated taxa and mucosal genes related to B-cell receptor signaling and RNA-processing.</p><p><strong>Conclusions: </strong>Persistent symptoms in qCD are mucosal transcriptional differences and fecal microbial features. These findings suggest a model in which altered immune regulation, microbial sulfur metabolism, and downstream epithelial and metabolic stress pathways contribute to symptom persistence despite quiescent inflammation, but this model requires mechanistic validation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alvin T George, Alexandra R McDermott, Alyse R Bedell, Allistair L Clark, Muskaan Mehra, Omer Liran, Rajsavi Anand, Robert Chernoff, Lauren C Capucci, Brennan M R Spiegel, David T Rubin
{"title":"The application of an artificial intelligence-enhanced virtual reality cognitive behavioral therapy tool is feasible and acceptable in patients with inflammatory bowel disease: A multicenter mixed methods pilot study.","authors":"Alvin T George, Alexandra R McDermott, Alyse R Bedell, Allistair L Clark, Muskaan Mehra, Omer Liran, Rajsavi Anand, Robert Chernoff, Lauren C Capucci, Brennan M R Spiegel, David T Rubin","doi":"10.1093/ibd/izag208","DOIUrl":"https://doi.org/10.1093/ibd/izag208","url":null,"abstract":"<p><strong>Background: </strong>Patients with inflammatory bowel disease (IBD) frequently experience anxiety, pain, and reduced quality of life. Cognitive behavioral therapy (CBT) is effective for anxiety, but access may be limited. We evaluated the feasibility and explored the potential clinical impact of an artificial intelligence-powered virtual reality CBT-based application (XAIA [eXtended Reality Artificially Intelligent Ally]) in patients with IBD.</p><p><strong>Methods: </strong>This was a multicenter, mixed-methods pilot study recruiting adults with IBD from the University of Chicago and Cedars-Sinai medical centers. Participants completed a single 30-minute session with the XAIA conversational avatar. Pain and anxiety were measured before and after the session using a visual analog pain scale and State-Trait Anxiety Inventory, respectively. Semi-structured interviews were conducted after the session to assess acceptability. Quantitative analysis was completed using paired t tests, and interview transcripts underwent thematic analysis.</p><p><strong>Results: </strong>Thirty-four participants (median age 34 years, 71% women, 59% with Crohn's disease) participated in this study. Qualitative analysis revealed high acceptability, with participants reporting feelings of safety, validation, and improved coping. Participants valued the immersive environment, conversational avatar, and ability to discuss sensitive topics without judgment. As an exploratory outcome, participants reported a statistically significant improvement in pain (-0.46; P = .011) and anxiety (-10.65; P < .001) immediately following a single session.</p><p><strong>Conclusions: </strong>A single artificial intelligence-driven virtual reality CBT-based session in patients with IBD was feasible and well accepted and demonstrated preliminary evidence for acute reductions in pain and anxiety scores. Immersive digital behavioral health interventions may represent a scalable adjunct to traditional mental health support among adults with IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guorong Chen, Shiyu Du, Hui Li, Huifen Wang, Huiting Zhu, Qin Zhang, Runhui Yang, Xuan Wu, Bing Shao, Yanli Zhang
{"title":"Multi-matrix metabolome and microbiome profiling in diarrhea-predominant irritable bowel syndrome and ulcerative colitis in remission with IBS-like symptoms.","authors":"Guorong Chen, Shiyu Du, Hui Li, Huifen Wang, Huiting Zhu, Qin Zhang, Runhui Yang, Xuan Wu, Bing Shao, Yanli Zhang","doi":"10.1093/ibd/izag243","DOIUrl":"https://doi.org/10.1093/ibd/izag243","url":null,"abstract":"<p><strong>Background: </strong>Irritable bowel syndrome (IBS)-like symptoms frequently persist in patients with ulcerative colitis (UC) in remission. Whether UC in remission with IBS-like symptoms (UCR-IBS) represents functional overlap with diarrhea-predominant IBS (IBS-D) or a distinct metabolic phenotype remains unclear.</p><p><strong>Methods: </strong>In this exploratory cross-sectional study, 39 patients with IBS-D, 21 with UCR-IBS, and 35 healthy controls were enrolled. Serum, urine, fecal, and colonic mucosal samples were collected. Untargeted metabolomics, targeted tryptophan profiling, fecal 16S ribosomal RNA gene sequencing, predicted microbial functional profiling, and microbe-metabolite association analyses were performed.</p><p><strong>Results: </strong>Tryptophan-related metabolism was altered in both patient groups, but the patterns differed across biological matrices. Compared with IBS-D, UCR-IBS showed higher serum N-formylkynurenine (NFK) concentrations, and fecal findings suggested reduced concentrations of microbiota-associated indole metabolites. Microbiome differences were modest, but predicted nicotinate/nicotinamide metabolism was enriched in UCR-IBS. Exploratory network analysis identified associations between tryptophan-related metabolites and selected bacterial genera in each group.</p><p><strong>Conclusions: </strong>Multi-matrix profiling shows tryptophan-related metabolic differences between mesalazine-treated UCR-IBS and IBS-D, highlighting higher serum NFK concentrations in UCR-IBS. These findings provide a basis for investigating host-microbiota metabolic relationships across systemic and intestinal compartments during UC remission.This trial was registered in the Chinese Clinical Trial Registry (ChiCTR; https://www.chictr.org.cn/) under registration number ChiCTR2200060224.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotte Lund, Milada Hagen, Vibeke Strande, May-Bente Bengtson, Tone Bergene Aabrekk, Raziye Boyar, Svein Oskar Frigstad, Kristina I Aass Holten, Øistein Hovde, Gert Huppertz-Hauss, Bjørn Christian Olsen, Ingunn Johansen, Randi Opheim, Gøri Perminow, Roald Torp, Vendel A Kristensen, Marte Lie Høivik
{"title":"Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort.","authors":"Charlotte Lund, Milada Hagen, Vibeke Strande, May-Bente Bengtson, Tone Bergene Aabrekk, Raziye Boyar, Svein Oskar Frigstad, Kristina I Aass Holten, Øistein Hovde, Gert Huppertz-Hauss, Bjørn Christian Olsen, Ingunn Johansen, Randi Opheim, Gøri Perminow, Roald Torp, Vendel A Kristensen, Marte Lie Høivik","doi":"10.1093/ibd/izag213","DOIUrl":"https://doi.org/10.1093/ibd/izag213","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the proportion of Crohn's disease (CD) and ulcerative colitis (UC) patients receiving work disability (WD) benefits with the corresponding proportion in the background population at diagnosis and after 1 year, and to assess associations between selected variables and WD.</p><p><strong>Methods: </strong>Adults from a population-based inception cohort with WD data at diagnosis and/or 1-year follow-up were included. WD was defined as receiving work assessment allowance (AAP) or disability pension (DP). Relative risks (RRs) for AAP and DP were calculated vs. national registry proportions stratified by age and sex, overall RRs were age standardized. Multivariable logistic regression assessed associations between WD and selected variables.</p><p><strong>Results: </strong>At diagnosis, risk of AAP was increased for UC (RR, 1.5; 95% confidence interval [CI], 1.1-2.1) and CD patients between 30-39 years old (RR, 2.8; 95% CI, 1.1-5.8). AAP risk was increased at 1-year for both UC (RR, 1.6; 95% CI, 1.1-2.4) and CD (RR, 3.6; 95% CI, 2.4-5.2). DP risk was comparable with the background population. Higher general self-efficacy and health-related quality of life were associated with lower odds of WD, whereas disease-activity variables were not. Older age, comorbidities, and lower education were also associated with increased odds of WD in UC.</p><p><strong>Conclusions: </strong>After 1 year, patients with UC and CD had increased risk of AAP. Lower general self-efficacy and poorer health-related quality of life were associated with higher WD, suggesting a potential window for targeted interventions to reduce AAP and prevent or delay DP.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}